About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 68435 record(s)
Req # A-2023-001360
Adverse Drug Reaction (ADR) for Midazolam. Report number: 001066753.Organization: Health Canada
February 2024
Req # A-2023-001363
Adverse Drug Reaction (ADR). Report number: 001051697.Organization: Health Canada
February 2024
Req # A-2015-000032
Documentation, forms, and paperwork relating to On-Site Evaluations done at Alexion Pharmaceuticals between December 3 - December 5 2008, Hoffman-La Roche between November 15 - November 20 2004, and Amgen Canada between February 12 - February 16…Organization: Health Canada
February 2024
Req # A-2018-001128
Any information pertaining to a recall, stop sale or any compliance and enforcement related activities involving Natural Product Number (NPN) 80037590 and NPN 80042116 licensed to Ferring Inc. from January 1, 2018 to November 13, 2018.Organization: Health Canada
February 2024
Req # A-2019-001814
Provide additional records for the Notice of Non-Compliance (NON) letter regarding liraglutide.Organization: Health Canada
February 2024
Req # A-2019-001949
All documentation related to the approval or access of Nurown in Canada or anything of relevance to communication between the Health Canada and Brainstorm Cell Therapeutics regarding Nurown since 2011 until March 24, 2020.Organization: Health Canada
February 2024
Req # A-2021-001996
Briefing notes and attachments regarding the January 17, 2022 authorization of PAXLOVID TM for patients with mild to moderate COVID-19 at high risk of developing serious disease from November 1, 2021 to February 1, 2022.Organization: Health Canada
February 2024
Req # A-2022-000881
All complaints posted against Lifeline Pharmaceuticals - in relation to health product advertising incidents. All information in relation to incidents received by Health Canada and those referred to an Advertising Preclearance Agency (APA) from 2021…Organization: Health Canada
February 2024
Req # A-2022-000919
The Rothmans, Benson & Hedges submission in response to consultation on the proposed Regulations Amending the Tobacco Products Regulations published in the Canada Gazette Part I on June 11, 2022.Organization: Health Canada
February 2024
Req # A-2022-000996
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Pharmacovigilance Practices (GVP) inspection of…Organization: Health Canada
February 2024